The patient has provided permission to publish the features of his case and his identity has been protected.
A Case of Recalcitrant Epidermolysis Bullosa Acquisita Responsive to Rituximab Therapy
Article first published online: 29 OCT 2012
© 2012 Wiley Periodicals, Inc.
Volume 31, Issue 2, pages 241–244, March/April 2014
How to Cite
McKinley, S. K., Huang, J. T., Tan, J., Kroshinsky, D. and Gellis, S. (2014), A Case of Recalcitrant Epidermolysis Bullosa Acquisita Responsive to Rituximab Therapy. Pediatric Dermatology, 31: 241–244. doi: 10.1111/pde.12006
- Issue published online: 9 MAR 2014
- Article first published online: 29 OCT 2012
Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disorder that occurs infrequently in children. Although typically associated with a good prognosis in children, there are rare cases that are refractory to treatment with conventional immunosuppressive therapy. Rituximab, an anti-CD20 monoclonal antibody, has been reported to be effective in the adult form of EBA. We report a case of a child with severe and recalcitrant EBA exhibiting a sustained response to treatment with rituximab.